The industry for Excessive Daytime Sleepiness (EDS) diagnosis is experiencing accelerated innovation as digital health integration and new diagnostic modalities reshape how clinicians identify and manage sleep disorders. Rising prevalence of sleep apnea and narcolepsy is driving Excessive Daytime Sleepiness EDS Diagnosis Market demand for precise tools, while at‐home testing and AI‐enabled platforms enhance diagnostic accuracy.
Market Size and Overview
The excessive daytime sleepiness (EDS) diagnosis market is estimated to be valued at USD 7.44 billion in 2025 and is expected to reach USD 13.95 billion by 2032, growing at a compound annual growth rate (CAGR) of 9.4% from 2025 to 2032.
With prevalence of sleep disorders rising by 12% between 2020 and 2024, industry size is poised for strong business growth. An evaluation of market revenue highlights accelerated adoption of AI‐enabled diagnostic tools and telehealth services. Recent market research underscores a shift toward at‐home wearable devices, reshaping industry trends and market forecast assumptions.
Market Segmentation
According to the latest Excessive Daytime Sleepiness EDS Diagnosis Market report, three core segments structure the landscape:
1. Diagnostic Technique: Patient Questionnaires; Polysomnography (PSG); Multiple Sleep Latency Test (MSLT); Actigraphy; EEG Monitoring. Dominant sub-segment: PSG accounted for over USD 3.35 Bn revenue in 2025. Fastest-growing: Actigraphy, with 18% volume growth in 2024 as clinics seek wearable convenience.
2. End User: Hospitals & Clinics; Sleep Centers; Diagnostic Laboratories; Home Healthcare. Dominant: Sleep Centers drove 48% of revenues in 2025. Fastest-growing: Home Healthcare, up 22% in 2025 owing to patient preference for at-home assessments.
3. Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Direct Sales. Dominant: Hospital Pharmacies maintained 60% of product revenues in 2025. Fastest-growing: Online Pharmacies, registering a 25% revenue uptick in 2025.
Market Drivers
One key market driver is the surge in digital health policy support and reimbursement expansion. In 2024, the U.S. Centers for Medicare & Medicaid Services increased coverage for home sleep apnea tests by 15%, fuelling broader acceptance of telehealth solutions. Concurrently, regulatory approvals for AI-based EEG analysis platforms rose by 28% in early 2025, reducing diagnostic turnaround times by up to 30%. These shifts underpin market dynamics, opening new market opportunities and mitigating traditional market challenges related to underdiagnosis and limited specialist access.
Segment Analysis
Focusing on Diagnostic Technique, Polysomnography remains the dominant revenue contributor, generating USD 3.35 Bn in 2025 owing to its comprehensive bio‐signal profiling. While the Excessive Daytime Sleepiness EDS Diagnosis Market share is influenced by high capital requirements of PSG systems, Actigraphy stands out as the fastest‐growing sub-segment, with shipments up 18% year-on-year in 2024. A case study at a European sleep center revealed that integrating actigraphy reduced patient throughput time by 20%, illustrating how portable sensors are redefining market growth strategies and service efficiency.
Consumer Behaviour Insights
Emerging Excessive Daytime Sleepiness EDS Diagnosis Market trends highlight a shift toward at-home testing and telemonitoring. A 2025 survey of 1,200 patients across North America showed 68% prefer at-home diagnostic kits over in-lab PSG due to convenience. In parallel, 55% cited pricing sensitivity—opting for tiered subscription models—while 47% demanded greater customization, such as mobile app integration for longitudinal data. Sustainability preferences are also evident: 36% of providers favor low-power wearable sensors, further influencing product development roadmaps and market growth.
Key Players
Major market players actively expanded portfolios and capacities in 2024–2025:
• Jazz Pharmaceuticals
• Takeda Pharmaceutical Company
• Harmony Biosciences
• Avadel Pharmaceuticals
• Philips Healthcare
• ResMed Inc.
• Natus Medical Inc.
• Itamar Medical Ltd.
• Nihon Kohden Corporation
• Embla Systems (Natus)
• Compumedics Limited
• GE Healthcare
• Somnomedics GmbH
• Brasseler SleepMed
Between 2024 and 2025, Philips Healthcare launched a wearable EEG headband achieving 22% penetration in Europe. ResMed expanded its at-home diagnostics portfolio by acquiring a telehealth startup, driving a 30% uplift in U.S. kit sales. Harmony Biosciences secured FDA approval for pitolisant in late 2024, boosting diagnostic referrals by 15%.
Key Winning Strategies Adopted by Key Players
1. ResMed’s AI-Driven Referral Platform (2025): Integration of machine learning triage reduced false negatives by 25%, cutting clinical evaluation time by 40%.
2. Harmony Biosciences’ Digital Adherence Program (2024): A gamified app improved therapy compliance for EDS patients by 18%, increasing repeat diagnostic orders.
3. Jazz Pharmaceuticals’ Genomic Screening Collaboration (2025): Partnership with a genomics firm enabled biomarker-guided EDS risk stratification, enhancing early diagnosis rates by 20% and setting a new benchmark for personalized diagnostics.
FAQs
1. Who are the dominant players in the Excessive Daytime Sleepiness EDS Diagnosis Market?
Dominant players include Jazz Pharmaceuticals, Takeda Pharmaceutical Company, Harmony Biosciences and Avadel Pharmaceuticals, alongside diagnostic equipment leaders such as Philips Healthcare and ResMed Inc.
2. What will be the size of the Excessive Daytime Sleepiness EDS Diagnosis Market in the coming years?
The market is projected to grow from USD 7.44 Bn in 2025 to USD 13.95 Bn by 2032, at a CAGR of 9.4% during the forecast period.
3. Which end-user segment has the largest growth opportunity?
The Home Healthcare segment exhibits the highest growth trajectory, with 22% expansion in 2025 as more patients opt for at-home testing kits and remote monitoring.
4. How will market development trends evolve over the next five years?
Advancements in AI-based analysis, wearable sensor miniaturization and telehealth integration will drive diagnostic efficiency, reduce costs and expand access, resulting in sustained market growth.
5. What is the nature of the competitive landscape and challenges in the Excessive Daytime Sleepiness EDS Diagnosis Market?
The landscape is fragmented, featuring pharmaceutical innovators and diagnostic equipment vendors. Key challenges include high device costs, stringent regulatory requirements and underdiagnosis in emerging regions.
6. What go-to-market strategies are commonly adopted in the Excessive Daytime Sleepiness EDS Diagnosis Market?
Strategies include digital referral platforms, subscription-based device models, strategic partnerships for genomic screening and patient adherence programs to enhance diagnostic throughput and business growth.
➢Get this Report in Japanese Language: 日中の過度の眠気EDS診断市場
➢Get this Report in Korean Language: 과도한주간졸음증EDS진단시장
➢Read More Related Articles- Sleeping Bags - Essential Gear for Camping Adventures
Author Bio:
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163)
Comments
0 comment